Lin Guo

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA

L. Harrold, V. Khaychuk, S. Kelly, 2021, Rheumatology and Therapy.

Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis

J. Kremer, L. Harrold, E. Alemao, 2020, Current medical research and opinion.

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, A. Armstrong, R. McLean, 2023, Advances in therapy.

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+

P. Moore, L. Harrold, V. Khaychuk, 2023, Rheumatology and Therapy.

Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry

D. Pappas, Lin Guo, J. O’brien, 2023, Arthritis Research & Therapy.